Mega-Merger: Quintiles, IMS Health to Combine
CRO giant and leading healthcare information provider merge to create a wide-ranging R&D-to-commerical services company, in a deal some contend could trigger a trend of larger CROs adding complementary non-clinical offerings.
Quintiles, the world's largest contract research organization (CRO), and information and technology juggernaut IMS Health have agreed to an all-stock merger to create a combined company with service offerings across the entire life sciences product lifecycle-from R&D through commercial to the emerging areas of real-world evidence and patient outcomes. To be officially named Quintiles IMS, the new organization, according to the companies, will boast one of the world’s largest portfolios of healthcare information; deep therapeutic, domain, regulatory, and commercial analytic expertise; and proprietary technology applications supported by more than 50,000 employees operating in 100 countries.
The combined company is worth $17.6 billion based on market capitalization and with $7.2 billion in pro forma revenue in 2015. Industry consultants such as ISR believe this dealmaking trend in the CRO space will likely continue, as the larger CROs look to add complementary services and mid-size companies attempt to quickly gain scale to try to keep up.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
